LipoFIT Analytic GmbH, a German developer of new methods for routine assessments of the risk of developing atherosclerosis, has raised €4 million in VC funding. Backers include SHS Gesellschaft für Beteiligungsmanagement, KfW Bankengruppe and Bayern Kapital.
LipoFIT Analytic GmbH is receiving growth financing in the amount of €4 million to help it transform an analytical technology developed by researchers at the University of Regensburg into diagnostic products. Funds provided by SHS Gesellschaft für Beteiligungsmanagement, a growth investor located in Tübingen, Germany; KfW Bankengruppe (ERP Startfonds); and Bayern Kapital are being invested in the company, which is located in Regensburg.
Volker Pfahlert, formerly Chief Executive at Dräger Medical AG, will add his talents to the management at LipoFIT as COO in charge of strategy, marketing and sales.
The technology of LipoFIT permits very quick analysis of the multitude of contents to be found in a single sample of bodily fluids. With this technology, practically the entirety of a person’s metabolism can be
determined quickly, precisely, and without great expense. This enables physicians working from complex clinical findings to make quick and finely tuned diagnoses, thereby considerably improving patients’ chances of recovery.
The scientific basis for this technology is the use of very strong magnetic fields for NMR spectroscopy (nuclear magnetic resonance spectroscopy). Magnetic-resonance tomography is already established as a form of imaging in human medicine. LipoFIT uses considerably stronger magnetic fields, applying these to an analysis of e.g. blood or urine samples.
All of the components of the sample are identified simultaneously. Unlike established biological or chemical
analytical approaches, the LipoFIT approach has the power of identifying not just individual elements (often with fluctuating levels of precision) but rather entire human metabolic processes – in their entirety, and with a high level of precision. Digital storage of the findings permits access to data for further evaluation and fresh examination later on, e.g. in light of new research findings.
LipoFIT Analytic GmbH was established in 2004 by biophysicists Prof. Dr. Dr. Hans Robert Kalbitzer, Associate Professor Dr. Werner Kremer and CEO Dr. Fritz Huber as a spin-off of the University of Regensburg. All of the partners of the company to date will continue their involvement in the company. In exchange for their investment, the new partners, with SHS Gesellschaft für Beteiligungsmanagement as lead investor, will receive around a 50-percent interest in the company. Fritz Huber will remain as CEO. Currently, the ten staff members at LipoFIT are already generating annual sales of around half a million euro. The company’s clients include major corporations in the pharmaceuticals sector, as well as several
university clinics. The company anticipates robust growth in the near future.
‘We are very pleased that, thanks to the assistance of our investors, we now have the opportunity introduce these processes to the broader market – processes developed over many years’ work and trials. The history of LipoFIT demonstrates how top-flight international research can also manifest itself in products and economic success. This drives medical advancements while creating jobs in the region at the same time’, LipoFIT founder and CEO Fritz Huber observes with regard to the company’s planned growth.
‘LipoFIT has enormous market potential. The technology offers a host of new applications that will meet an acute need in the hospital setting while offering genuine progress for patients. We will support the management not just financially but in terms of strategy in staffing as well, to permit broad application of the innovative methods developed by LipoFIT. That we managed to win over Dr. Volker Pfahlert for this company is an important step in this direction’, notes Dr. Bernhard Schirmers, Partner at SHS Gesellschaft für Beteiligungsmanagement, commenting on his company’s investment in LipoFIT.
Effective immediately, Dr. Volker Pfahlert will be strengthening LipoFIT as COO. Pfahlert brings a rich résumé of experience in outstanding positions in the medical technology and diagnostics industry. Through the
end of 2007, he was Chief Executive at Dräger Medical AG&Co.KG and a member of the Executive Board at Drägerwerk AG. Prior to that, as an executive at Roche Diagnostics in Switzerland, and in Mannheim and
Penzberg, Germany, he headed two divisions: Roche Professional Diagnostics and Roche Applied Sciences. Volker Pfahlert is a lecturer at the University of Mannheim, where he lectures on the application of
concepts in marketing strategy.
‘I see in the LipoFIT technology and opportunity to install new standards in diagnostic fields that, to date, have not satisfactorily been covered. I look forward to working in this small yet highly innovative company and am certain that LipoFIT is going to experience strong growth’, remarks Volker Pfahlert about his new employer.
About LipoFIT Analytic GmbH
LipoFIT was launched in April 2004 with a new, patented method for routine assessments of the risk of developing atherosclerosis. Based on this expertise, the company has now evolved into Europe’s largest
provider in the NMR analytics field. LipoFIT specializes in the analysis of hundreds of substances in a wide variety of biological fluids, including, particularly, in high-capacity operation. In addition to this, LipoFIT offers a broad spectrum of ultra-modern analytics services in the medicalpharmacological area.